metabolic clearance rate

Summary

Summary: Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.

Top Publications

  1. ncbi Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches
    Kiyomi Ito
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL, UK
    Pharm Res 22:103-12. 2005
  2. ncbi Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 47:47-59. 2008
  3. ncbi Emerging evidence of the impact of kidney disease on drug metabolism and transport
    T D Nolin
    Division of Nephrology and Transplantation, Department of Medicine, Maine Medical Center, Portland, Maine, USA
    Clin Pharmacol Ther 83:898-903. 2008
  4. ncbi Prediction of drug clearance in children: impact of allometric exponents, body weight, and age
    Iftekhar Mahmood
    From the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Ther Drug Monit 29:271-8. 2007
  5. ncbi Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
    L A Hammond
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78829, USA
    J Clin Oncol 17:2604-13. 1999
  6. ncbi Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer
    S D Baker
    The Johns Hopkins Oncology Center, Baltimore, Maryland 21287, USA
    Clin Cancer Res 5:309-17. 1999
  7. ncbi The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria
    Paul N Newton
    Faculty of Tropical Medicine, Mahidol University, 420 6 Rajvithi Rd, Bangkok 10400, Thailand
    Eur J Clin Pharmacol 62:1003-9. 2006
  8. ncbi A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
    F Forrer
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 31:1257-62. 2004
  9. ncbi Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin
    Erik Vegt
    Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 47:432-6. 2006
  10. ncbi Population clinical pharmacology of children: modelling covariate effects
    Brian J Anderson
    Department of Anaesthesiology, University of Auckland, Auckland, New Zealand
    Eur J Pediatr 165:819-29. 2006

Detail Information

Publications312 found, 100 shown here

  1. ncbi Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches
    Kiyomi Ito
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL, UK
    Pharm Res 22:103-12. 2005
    ....
  2. ncbi Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 47:47-59. 2008
    ....
  3. ncbi Emerging evidence of the impact of kidney disease on drug metabolism and transport
    T D Nolin
    Division of Nephrology and Transplantation, Department of Medicine, Maine Medical Center, Portland, Maine, USA
    Clin Pharmacol Ther 83:898-903. 2008
    ..This is particularly so in the case of drugs with narrow therapeutic windows and may translate into clinically significant variations in exposure and response...
  4. ncbi Prediction of drug clearance in children: impact of allometric exponents, body weight, and age
    Iftekhar Mahmood
    From the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Ther Drug Monit 29:271-8. 2007
    ..75 should be replaced by the exponent of the allometric equation developed for that drug...
  5. ncbi Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
    L A Hammond
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78829, USA
    J Clin Oncol 17:2604-13. 1999
    ....
  6. ncbi Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer
    S D Baker
    The Johns Hopkins Oncology Center, Baltimore, Maryland 21287, USA
    Clin Cancer Res 5:309-17. 1999
    ..The primary elimination pathway for TMZ is by pH-dependent degradation to MTIC and further degradation to AIC. Incomplete recovery of radioactivity may be explained by the incorporation of AIC into nucleic acids...
  7. ncbi The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria
    Paul N Newton
    Faculty of Tropical Medicine, Mahidol University, 420 6 Rajvithi Rd, Bangkok 10400, Thailand
    Eur J Clin Pharmacol 62:1003-9. 2006
    ..The choice of doses used has been empirical. To inform dosage recommendations we assessed the pharmacokinetics of intravenous artesunate after the first dose...
  8. ncbi A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
    F Forrer
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 31:1257-62. 2004
    ....
  9. ncbi Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin
    Erik Vegt
    Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 47:432-6. 2006
    ..Here, we studied the effects of infusion of low doses of the plasma expander succinylated gelatin (GELO) on the renal uptake of 111In-labeled octreotide (111In-OCT)...
  10. ncbi Population clinical pharmacology of children: modelling covariate effects
    Brian J Anderson
    Department of Anaesthesiology, University of Auckland, Auckland, New Zealand
    Eur J Pediatr 165:819-29. 2006
    ..Population modelling using mixed effects models provides a means to study variability in paediatric drug responses among individuals representative of those in whom the drug will be used clinically...
  11. ncbi Metabolic deficiencies in alcohol dehydrogenase Adh1, Adh3, and Adh4 null mutant mice. Overlapping roles of Adh1 and Adh4 in ethanol clearance and metabolism of retinol to retinoic acid
    L Deltour
    Gene Regulation Program, Burnham Institute, La Jolla, California 92037, USA
    J Biol Chem 274:16796-801. 1999
    ..Redundant roles for Adh1 and Adh4 in retinoic acid production may explain the apparent normal development of mutant mice...
  12. ncbi Monoclonal antibody pharmacokinetics and pharmacodynamics
    W Wang
    Department of Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, West Point, Pennsylvania, USA
    Clin Pharmacol Ther 84:548-58. 2008
    ..This article attempts to provide a brief overview of the main determinants of antibody pharmacokinetics and pharmacodynamics. Clinical Pharmacology & Therapeutics (2008); 84, 5, 548-558 doi:10.1038/clpt.2008.170...
  13. ncbi Augmented renal clearance in septic patients and implications for vancomycin optimisation
    João Pedro Baptista
    Servico de Medicina Intensiva, Hospitais da Universidade de Coimbra, Praceta Professor Mota Pinto 3000 075, Coimbra, Portugal
    Int J Antimicrob Agents 39:420-3. 2012
    ..05 per day). The correlation between CL(Cr) and serum vancomycin on D(1) was -0.57 (P<0.001). ARC was strongly associated with subtherapeutic vancomycin serum concentrations on the first 3 days of treatment...
  14. ncbi Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations
    Andrew A Udy
    Department of Intensive Care Medicine, University of Queensland, Herston, Brisbane, QLD, Australia
    Chest 142:30-9. 2012
    ..Changes in renal function in this setting can significantly impact the probability of achieving such targets...
  15. ncbi Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid
    Sean C Semple
    Inex Pharmaceuticals Corporation, 100 8900 Glenlyon Parkway, Burnaby, BC, Canada, V5J 5J8
    J Pharmacol Exp Ther 312:1020-6. 2005
    ..These studies have important implications for the evaluation and therapeutic use of liposomal formulations of nucleic acid, as well as the potential development of liposomal vaccines...
  16. ncbi Inter-individual variability in propofol pharmacokinetics in preterm and term neonates
    K Allegaert
    Neonatal Intensive Care Unit, Division of Woman and Child, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Br J Anaesth 99:864-70. 2007
    ..To document covariates which contribute to inter-individual variability in propofol pharmacokinetics in preterm and term neonates...
  17. pmc Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
    Brian J Anderson
    Neonatal Intensive Care Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Br J Clin Pharmacol 63:75-84. 2007
    ..Size, standardized using allometric models, was the primary covariate used in our analysis...
  18. pmc Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect
    Gregory L Kearns
    Director, Pharmacogenetics Core Laboratory, Division of Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    Drug Metab Dispos 38:894-7. 2010
    ..0001) and the apparent elimination rate constant (K(el); p = 0.0012); no significant genotype-phenotype relationships were observed for omeprazole...
  19. pmc A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance
    João Pedro Baptista
    Servico de Medicina Intensiva, Hospitais da Universidade de Coimbra, EPEPraceta Prof Mota Pinto, Av Bissaya Barreto 3000 075 Coimbra, Portugal
    Crit Care 15:R139. 2011
    ..To date, these estimates have not been rigorously validated in those with augmented clearances, resulting in potentially inaccurate drug prescription...
  20. ncbi Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers
    D I Min
    College of Pharmacy, Department of Internal Medicine, The University of Iowa, Iowa City 52242, USA
    Clin Pharmacol Ther 68:478-86. 2000
    ..9 +/- 6.8 ng x hr/mL per milligram and 24.2 +/- 4.6 ng x hr/mL per milligram, respectively, in white volunteers (P = .023). These findings suggest that disposition of cyclosporine is dependent both on race and on gender...
  21. ncbi Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice
    Tatsuhiro Ishida
    Department of Pharmacokinetics and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, The University of Tokushima, 1 78 1, Sho machi, Tokushima 770 8505, Japan
    J Control Release 95:403-12. 2004
    ..The results reported herein have a considerable impact on the design and engineering of liposomal formulations for use in multiple drug therapy as well as in therapy that involves the use of liposomal drugs...
  22. ncbi Augmented renal clearance in the Intensive Care Unit: an illustrative case series
    Andrew A Udy
    Burns, Trauma and Critical Care Research Centre, University of Queensland, Brisbane, Queensland, Australia
    Int J Antimicrob Agents 35:606-8. 2010
    ..TDM, or at least a measured creatinine clearance, should be considered early in this setting to allow the optimisation of antibiotic exposure...
  23. pmc Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria
    Claire Nealon
    Department of Infectious Diseases, St George s Hospital Medical School, London SW17 ORE, United Kingdom
    Antimicrob Agents Chemother 46:3933-9. 2002
    ..001 to 1.58 liters/kg/min). There were no major adverse events attributable to ARS. Parasite clearance kinetics were comparable between the two treatment groups. These results support the use of i.m. ARS in children with severe malaria...
  24. ncbi Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats
    Julliette E M van Eerd
    Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 47:528-33. 2006
    ..In the present study, we analyzed the effects of several plasma expanders on the renal uptake of 111In-octreotide in rats and mice...
  25. ncbi Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 49:259-68. 2010
    ..A decrease in the dose and/or an increase in the administration interval in these patients may be appropriate. In patients with ESRD, dabigatran can be partly removed from the plasma by haemodialysis...
  26. ncbi Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients
    Maria del Mar Fernández de Gatta Garcia
    Pharmacy Department, University of Salamanca, Salamanca, Spain
    Intensive Care Med 33:279-85. 2007
    ..To identify the variables affecting vancomycin pharmacokinetics in medical ICU patients and to evaluate the potential efficacy of dosage schedules by PK/PD analysis...
  27. ncbi Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Michinori Ogura
    Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan
    Cancer Sci 101:2054-8. 2010
    ..The recommended dose for this schedule in phase II trials is 120 mg/m(2) . The acceptable safety profile and high ORR warrant further investigation of bendamustine in relapsed or refractory indolent B-NHL and MCL...
  28. ncbi The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice
    Sudhir H Ranganath
    Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore 117576, Singapore
    Biomaterials 31:5199-207. 2010
    ....
  29. ncbi Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children
    Trevor N Johnson
    Simcyp Limited, Sheffield, UK
    Clin Pharmacokinet 45:931-56. 2006
    ..The algorithms have now been extended to predict clearance and its variability in paediatric populations by incorporating information on developmental physiology and the ontogeny of specific cytochrome P450s...
  30. ncbi Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles
    Tsutomu Ishihara
    Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, 5 1 Oe honmachi, Kumamoto, 862 0973, Japan
    Pharm Res 26:2270-9. 2009
    ..In this study, we tested whether the accelerated blood clearance (ABC) phenomenon is observed with NP-L20 and other PEG-modified PLA-nanoparticles in rats...
  31. ncbi T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes
    Hiroyuki Koide
    Department of Medical Biochemistry and Global COE Program, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Suruga ku, Shizuoka, Japan
    Int J Pharm 392:218-23. 2010
    ..The present study provides important information for the future development of liposomal medicines...
  32. ncbi Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection
    Tatsuhiro Ishida
    Department of Pharmacokinetics and Biopharmaceutics, Subdivision of Biopharmaceutical Sciences, Institute of Health Biosciences, The University of Tokushima, 1 78 1, Sho machi, Tokushima 770 8505, Japan
    J Control Release 115:251-8. 2006
    ..Our observations may thus have important implications for the development, evaluation and therapeutic use of liposomal cytotoxic drug formulations requiring multiple injection schemes...
  33. ncbi Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)
    Alex Sparreboom
    National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:4136-43. 2005
    ..To compare the preclinical and clinical pharmacokinetic properties of paclitaxel formulated as a Cremophor-free, albumin-bound nanoparticle (ABI-007) and formulated in Cremophor-ethanol (Taxol)...
  34. ncbi Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes
    Xinyu Wang
    Department of Pharmacokinetics and Biopharmaceutics, Subdivision of Biopharmaceutical Sciences, Institute of Health Biosciences, The University of Tokushima, 1 78 1, Sho machi, Tokushima 770 8505, Japan
    J Control Release 119:236-44. 2007
    ..Furthermore, our findings as described here raise important concerns with regard to the safety and efficiency of liposomes currently under development for clinical use...
  35. ncbi Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients
    S Irtan
    Department of Paediatric Pharmacology and Pharmacogenetics, Hospital Robert Debre, Paris, France
    Ther Drug Monit 29:96-102. 2007
    ..The body weight and the posttransplantation delay were identified to influence PK interindividual variability of CsA and were included in the Bayesian estimator developed, which could be helpful in further clinical trials...
  36. ncbi Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors
    Galith Abourbeh
    Department of Medical Biophysics and Nuclear Medicine, Hadassah Hebrew University, Jerusalem 91120, Israel
    Nucl Med Biol 34:55-70. 2007
    ..Detailed pharmacokinetic characterization of this bioprobe could assist in the development of a kinetic model that would afford accurate measurement of EGFR content in tumors...
  37. ncbi Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A
    Neha M Shah
    Department of Pharmaceutics and Pharmaceutical Technology, A R College of Pharmacy, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India
    J Nanosci Nanotechnol 6:2967-73. 2006
    ....
  38. ncbi Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone
    Andrea D Coviello
    Department of Medicine, Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Clin Endocrinol Metab 91:4669-75. 2006
    ..We hypothesized that older men have lower apparent testosterone metabolic clearance rates (aMCR-T) that contribute to higher testosterone levels...
  39. ncbi Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
    Staffan Ohlsson Rosenborg
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 64:1175-9. 2008
    ..The aim of this study was to compare the impact of the CYP2C19*17 allele on omeprazole single-dose kinetics with escitalopram exposure at steady state in volunteers genotyped as either CYP2C19*17/*17 or CYP2C19*1/*1...
  40. ncbi Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors
    Anne Charlotte Dubbelman
    Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Drug Metab Dispos 40:313-21. 2012
    ..4% in urine and feces. Overall, no major metabolites of eribulin were detected in plasma. Eribulin is eliminated primarily unchanged in feces, whereas urine constitutes a minor route of elimination...
  41. pmc Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates
    S Fanta
    Department of Clinical Pharmacology, University of Helsinki, and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 64:772-84. 2007
    ..To use population pharmacokinetic modelling to characterize the influence of developmental and demographic factors on the pharmacokinetic variability of ciclosporin...
  42. ncbi Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans
    Oliver Langer
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Vienna, Austria
    J Nucl Med 46:1835-41. 2005
    ....
  43. ncbi Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats
    Tapan K Jain
    Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Mol Pharm 5:316-27. 2008
    ..In conclusion, our MNPs did not cause long-term changes in the liver enzyme levels or induce oxidative stress and thus can be safely used for drug delivery and imaging applications...
  44. ncbi Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model
    Mariska Y M Peeters
    Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands
    Clin Pharmacokinet 49:269-75. 2010
    ..Both allometric models based on bodyweight alone may be of use to predict propofol clearance in individuals older than 2 years. Approaches that also incorporate maturation are required to predict clearance under the age of 2 years...
  45. ncbi Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study
    Donghwan Lee
    Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea
    Clin Ther 33:2038-53. 2011
    ..A sustained-release (SR) formulation of cilostazol was recently developed in Korea and was expected to yield a lower C(max) and a similar AUC to the immediate-release (IR) formulation...
  46. ncbi The effect of Fc glycan forms on human IgG2 antibody clearance in humans
    Xiaoyu Chen
    Department of Analytical and Formulation Sciences, Amgen, Thousand Oaks, CA 91320, USA
    Glycobiology 19:240-9. 2009
    ..These results confirm that antibody clearance is not significantly affected by the Fc glycan structure and provide evidence for the presence of circulating mannosidase activity in humans...
  47. pmc Bile acid sequestration reduces plasma glucose levels in db/db mice by increasing its metabolic clearance rate
    Maxi Meissner
    Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    PLoS ONE 6:e24564. 2011
    ..We hypothesized that sequestrant-induced changes in hepatic glucose metabolism would underlie reduced plasma glucose levels. Therefore, in vivo glucose metabolism was assessed in db/db mice on and off BAS using tracer methodology...
  48. ncbi Region specific distribution of levomepromazine in the human brain
    J Kornhuber
    Department of Psychiatry, University of Erlangen, Germany
    J Neural Transm 113:387-97. 2006
    ..The aim of this study was to examine concentrations of levomepromazine and its metabolite desmethyl-levomepromazine in different regions of human brain and in relationship to drug-free time...
  49. ncbi [Development of software for data analysis by therapeutic drug monitoring of teicoplanin, a glycopeptide antibiotic]
    Toshiro Niwa
    Post marketing Development Research Center, Fujisawa Pharmaceutical Co, Ltd, 3 4 7, Doshomachi, Chuo Ku, Osaka 541 8514, Japan
    Jpn J Antibiot 57:413-9. 2004
    ..A series of work from data input to graph drawing or printing of results could efficiently carried out with the best of use of this software, suggesting that this software is now available in clinical practice...
  50. pmc Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group
    J Lipman
    University of Queensland, Brisbane, Queensland, Australia
    Antimicrob Agents Chemother 42:2235-9. 1998
    ..Except for some initial accumulation on D2, no further accumulation occurred in patients without renal failure. Ciprofloxacin should be administered i.v. at a dosage of 400 mg q8h for severe sepsis...
  51. ncbi Radiation dose estimates in humans for (11)C-acetate whole-body PET
    Marc A Seltzer
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, University of California at Los Angeles School of Medicine, Los Angeles, California, USA
    J Nucl Med 45:1233-6. 2004
    ..Dynamic whole-body (11)C-acetate PET was therefore performed on 6 healthy human volunteers. Measured dose estimates for all target organs were compared with the existing ORISE values...
  52. ncbi Plasma renin activity and metabolic clearance rate of angiotensin II in the unstressed aging rat
    C Baylis
    Department of Physiology, West Virginia University, Morgantown 26506 9229, USA
    Mech Ageing Dev 97:163-72. 1997
    ..months) and old (18-20 months) rats to assess the impact of aging on baseline renin activity (PRA) and metabolic clearance rate (MCR) of angiotensin II (ANG II)...
  53. ncbi Vancomycin: pharmacokinetics and administration regimens in neonates
    Matthijs de Hoog
    Department of Pediatrics, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Clin Pharmacokinet 43:417-40. 2004
    ..Patients with renal failure and other special subpopulations, such as patients exposed to ECMO or indomethacin, need to be monitored more closely...
  54. pmc Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers
    S Q Zhang
    Department of Pharmacy, Uppsala University, Uppsala, Sweden
    Br J Clin Pharmacol 52:377-85. 2001
    ..However, dihydroartemisinin elimination was inhibited by artemisinin. Artemisinin induced its own elimination even 5 days after a single oral dose. There was no evidence for the formation of dihydroartemisinin from artemisinin...
  55. ncbi The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles
    Marianne Geiser
    Institute of Anatomy, University of Bern, Baltzerstrasse 2, CH 3000 Bern 9, Switzerland
    Am J Respir Cell Mol Biol 38:371-6. 2008
    ....
  56. ncbi Indication for different mechanisms of kidney uptake of radiolabeled peptides
    Martin Gotthardt
    Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    J Nucl Med 48:596-601. 2007
    ..Therefore, we evaluated the ability of several agents to inhibit the renal accumulation of different radiopeptides...
  57. ncbi Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia
    F Albertioni
    Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden
    Clin Cancer Res 4:653-8. 1998
    ..Furthermore, the results emphasize the differences between the pharmacokinetics of plasma CdA and those of the metabolites in circulating leukemic cells...
  58. ncbi Inhalation of poorly soluble particles. I. Differences in inflammatory response and clearance during exposure
    R T Cullen
    Institute of Occupational Medicine, 8 Roxburgh Place, Edinburgh EH8 9SU, United Kingdom
    Inhal Toxicol 12:1089-111. 2000
    ..The explanation that the different responses are due to the different particle size distributions of the two dust types is examined in a companion paper (Tran et al., this issue)...
  59. ncbi Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
    James P Thomas
    University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, 600 Highland Ave, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 50:465-72. 2002
    ..We conducted a phase I trial and pharmacokinetic study of flavopiridol given as a 72-h continuous intravenous infusion repeated every 2 weeks...
  60. ncbi Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method
    Yoshihiro Shibata
    Drug Metabolism, Tsukuba Research Institute, Banyu Pharmaceutical Co, Ltd, Ibaraki, Japan
    Drug Metab Dispos 30:892-6. 2002
    ....
  61. ncbi (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab
    Lars R Perk
    Department of Otolaryngology Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
    J Nucl Med 46:1898-906. 2005
    ..Cetuximab was selected as a model mAb because it abundantly internalizes after binding to the epidermal growth factor receptor...
  62. ncbi Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations
    María del Mar Fernández De Gatta
    Pharmacy Department, University of Salamanca, Avda Campo Charro s n, Salamanca, Spain
    Clin Pharmacokinet 41:115-35. 2002
    ..This type of study is needed so that techniques such as Bayesian forecasting can be applied to optimise immunosuppressive therapy in paediatric transplant patients...
  63. ncbi Morphine glucuronidation in preterm neonates, infants and children younger than 3 years
    Catherijne A J Knibbe
    Department of Clinical Pharmacy, St Antonius Hospital, 3430 EM Nieuwegein, The Netherlands
    Clin Pharmacokinet 48:371-85. 2009
    ....
  64. ncbi Evaluation of PET ligands (+)N-[(11)C]ethyl-3-piperidyl benzilate and (+)N-[(11)C]propyl-3-piperidyl benzilate for muscarinic cholinergic receptors: a PET study with microdialysis in comparison with (+)N-[(11)C]methyl-3-piperidyl benzilate in the consciou
    S Nishiyama
    Central Research Laboratory, Hamamatsu Photonics K. K, Hamakita, Shizuoka, Japan
    Synapse 40:159-69. 2001
    ....
  65. pmc Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria
    T Q Binh
    Tropical Diseases Research Center, Cho Ray Hospital, Ho Chi Minh City, Vietnam
    Br J Clin Pharmacol 51:541-6. 2001
    ..Based on our mean AUC measurements, it appears that equal doses of DHA and ARTS (mg basis) should give equivalent systemic exposure to bioactive DHA in uncomplicated falciparum malaria...
  66. ncbi Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography
    Lars R Perk
    Department of Otolaryngology Head and Neck Surgery, VU University Medical Centre, De Boelelaan 1117, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 33:1337-45. 2006
    ..To evaluate whether (89)Zr can be used as a PET surrogate label for quantification of (90)Y-ibritumomab tiuxetan ((90)Y-Zevalin) biodistribution and dosimetry before myeloablative radioimmunotherapy...
  67. ncbi Patients with ovarian cancer have elevated (51)Cr-EDTA plasma clearance early post-operatively
    S S Nielsen
    Department of Clinical Physiology and Nuclear Medicine, Skejby Sygehus, Aarhus University Hospital, Brendstrupgaardsvej, DK 8200 Aarhus N, Denmark
    Nucl Med Commun 23:917-20. 2002
    ..It is concluded that patients with ovarian cancer have significantly higher Clp(EDTA) in the early post-operative phase than similar patients with Clp(EDTA) measured late post-operatively...
  68. ncbi Effect of fluvoxamine on the pharmacokinetics of quinidine
    P Damkier
    Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense University
    Eur J Clin Pharmacol 55:451-6. 1999
    ..To investigate the possible involvement of cytochromes CYP1A2 and CYP2C19 in the in vivo oxidative metabolism of quinidine...
  69. ncbi A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy
    Inga Buchmann
    Department of Nuclear Medicine, University Hospital, Ulm, Germany
    Eur J Nucl Med Mol Imaging 30:667-73. 2003
    ..Thus, it appears superior to anti-CD45 mAb YTH 24.5 in selectively increasing the marrow dose and avoiding extramedullary organ toxicity...
  70. ncbi Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration
    S C Wallis
    Division of Anaesthesiology and Critical Care, University of Queensland, Herston Road, Herston, Brisbane, Queensland, Australia
    Intensive Care Med 27:665-72. 2001
    ..h l-1. CONCLUSIONS: Intravenous ciprofloxacin 600 mg/day in critically ill patients using this form of CRRT produced adequate plasma levels for many resistant microbes found in intensive care units...
  71. ncbi Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine
    Dirk Pauleit
    Clinic of Nuclear Medicine, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
    Eur J Nucl Med Mol Imaging 30:519-24. 2003
    ..5.3% ID/h). The highest absorbed dose was found for the urinary bladder wall. The effective dose according to ICRP 60 was 16.5 micro Sv/MBq for adults, which would lead to an effective dose of 6.1 mSv in a PET study using 370 MBq FET...
  72. ncbi Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
    Sven Björkman
    Hospital Pharmacy, Malmo University Hospital, Malmo, Sweden
    Clin Pharmacokinet 45:1-11. 2006
    ..Neither of the methods can be used as a substitute for actual clinical studies...
  73. pmc Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models
    Elke H J Krekels
    Division of Pharmacology, Leiden Amsterdam Center for Drug Research, Leiden, The Netherlands
    Pharm Res 28:797-811. 2011
    ..One covariate model was based on a systematic covariate analysis, the other on fixed allometric scaling principles...
  74. ncbi The effects of pregnancy on ethanol clearance
    Thomas M Badger
    Arkansas Children s Nutrition Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Life Sci 77:2111-26. 2005
    ..The greater ethanol clearance results in lower tissue ethanol concentrations achieved during pregnancy for a given dose, and this may have clinical significance as a mechanism to protect the growing fetus from ethanol toxicity...
  75. pmc Radiation dosimetry of 82Rb in humans under pharmacologic stress
    Srinivasan Senthamizhchelvan
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA
    J Nucl Med 52:485-91. 2011
    ..Using human biokinetic measurements, in vivo, we recently reported on the resting-state dosimetry of this agent. The objective of this study was to obtain (82)Rb dose estimates under stress...
  76. ncbi Radiation-absorbed dose from 201Tl-thallous chloride
    Stephen R Thomas
    Department of Radiology, University of Cincinnati, College of Medicine, Cincinnati, OH 45267 0579, USA
    J Nucl Med 46:502-8. 2005
    ....
  77. ncbi Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery
    Mariska Y M Peeters
    Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands
    Anesthesiology 104:466-74. 2006
    ..To support safe and effective use of propofol in nonventilated children after major surgery, a model for propofol pharmacokinetics and pharmacodynamics is described...
  78. ncbi Particle size-dependent triggering of accelerated blood clearance phenomenon
    Hiroyuki Koide
    Department of Medical Biochemistry and Global COE Program, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52 1 Yada, Suruga ku, Shizuoka 422 8526, Japan
    Int J Pharm 362:197-200. 2008
    ..Our study provides important information for developing both drug and gene delivery systems by means of nanocarriers...
  79. ncbi Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs
    L Simonsen
    Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Diabetologia 49:706-12. 2006
    ..Exendin-4 is less prone to enzymatic degradation, but it is still unclear what other factors contribute to the increased metabolic stability...
  80. ncbi Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes
    Hee Dong Han
    Bioactive Molecules Delivery and Control Research Team, Korea Research Institute of Chemical Technology, Yuseong, Daejeon, South Korea
    J Control Release 120:161-8. 2007
    ..This study suggests that the incorporation of the comblike polymer on the liposomal membrane is a promising tool to further improve circulation time of liposomes in tumor-bearing mice...
  81. ncbi MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan
    Darrell R Fisher
    Radioisotopes Program, Pacific Northwest National Laboratory, Richland, Washington, USA
    J Nucl Med 50:644-52. 2009
    ..In this study, we evaluated the organ radiation absorbed doses from intravenously administered (111)In- and (90)Y-ibritumomab tiuxetan...
  82. ncbi Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin
    Awesh Kumar Yadav
    Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr Hari Singh Gour University, Sagar, India
    Nanomedicine 3:246-57. 2007
    ..The DOX-loaded HA-PEG-PLGA nanoparticles reduced tumor volume significantly as compared with MPEG-PLGA nanoparticles...
  83. ncbi Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study
    S Willmann
    Competence Center Systems Biology, Bayer Technology Services GmbH, Leverkusen, Germany
    Clin Pharmacol Ther 86:634-43. 2009
    ..Importantly, neonates of mothers with the ultrarapid CYP2D6 genotype and neonates of mothers who are extensive metabolizers have comparable risks of opioid poisoning...
  84. ncbi 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation
    Raffaella Rossin
    Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Nucl Med 46:1210-8. 2005
    ..The purpose of this study was to evaluate 64Cu-radiolabeled folate-conjugated shell cross-linked nanoparticles (SCKs) as candidate agents to shuttle radionuclides and drugs into tumors overexpressing the folate receptor (FR)...
  85. ncbi Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types
    Yutaka Kanda
    Tokyo Research Laboratories, Kyowa Hakko Kogyo Co, Ltd, 3 6 6 Asahi machi, Machida shi, Tokyo 194 8533, Japan
    Glycobiology 17:104-18. 2007
    ..The present study provides basic information on the effects of core fucose-lacking N-linked Fc oligosaccharides on antibody biological activities...
  86. pmc Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats
    Lisa H Xie
    Department of Pharmacology, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910 7500, USA
    Malar J 8:112. 2009
    ..So far, however, the tissue distribution and metabolic profile of DHA data are not available from animal and humans...
  87. ncbi Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients
    Anna Ferrari
    Division of Toxicology and Clinical Pharmacology, University Centre for Adaptive Disorders and Headache, Section Modena II, University of Modena and Reggio Emilia, Modena, Italy
    Eur J Clin Pharmacol 64:489-95. 2008
    ..However, almost one third of patients in clinical trials fail to have headache relief after oral administration of sumatriptan...
  88. ncbi Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy
    Sophia Koukouraki
    Medical PET Group Biological Imaging E0601, Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
    Eur J Nucl Med Mol Imaging 33:1115-22. 2006
    ....
  89. ncbi Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition
    Patrick Poulin
    F Hoffmann La Roche Ltd, Pharmaceuticals Division, Non Clinical Development Drug Safety, PRNS Bau 69 101, CH 4070 Basel, Switzerland
    J Pharm Sci 91:1358-70. 2002
    ....
  90. pmc Tikhonov adaptively regularized gamma variate fitting to assess plasma clearance of inert renal markers
    Carl A Wesolowski
    Nuclear Medicine, The General Hospital, HSC, 300 Prince Philip Drive, St John s, NF A1B 3V6, Canada
    J Pharmacokinet Pharmacodyn 37:435-74. 2010
    ....
  91. ncbi Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept
    Iftekhar Mahmood
    Office of Blood Review and Research, Center for Biologic Evaluation and Research, Food and Drug Administration, 1451 Rockville Pike, MD 20852, USA
    Drug Metabol Drug Interact 24:57-81. 2009
    ..Although exponent 0.75 occasionally provided a good prediction of human drug clearance for a given drug for a given species, overall, the method is highly erratic and unreliable...
  92. ncbi Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing
    Catherine S C Bouman
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
    Intensive Care Med 32:2013-9. 2006
    ..We compared the observed Cl(CVVH) (SC x Q(uf)) with the estimated Cl(CVVH) (estimated F(UP) x Q(uf)) and determined the effect on the maintenance dose multiplication factor (MDMF)...
  93. pmc Prediction of drug clearance in children from adults: a comparison of several allometric methods
    Iftekhar Mahmood
    Clinical Pharmacology and Toxicology Branch, Office of Drug Evaluation VI, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Br J Clin Pharmacol 61:545-57. 2006
    ..75; and (iii) to propose a new approach (if any) based on the findings of the current evaluation...
  94. pmc Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor
    Robert Jordan
    SIGA Technologies, Inc, 4575 SW Research Way, Corvallis, OR 97330, USA
    Antimicrob Agents Chemother 52:1721-7. 2008
    ....
  95. ncbi Pharmacokinetics and dosage regimen of ceftriaxone in buffalo calves
    M S Dardi
    Department of Pharmacology and Toxicology, College of Veterinary Sciences, Punjab Agricultural University, Ludhiana 141 004, India
    Vet Res Commun 28:331-8. 2004
    ..To maintain a minimum therapeutic concentration of 1 microg/ml, a satisfactory intravenous dosage regimen of ceftriaxone in buffalo calves is 13 mg/kg repeated at 12 h intervals...
  96. ncbi Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection
    Huadong Tang
    Department of Pharmaceutical Sciences, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA
    Drug Metab Dispos 33:1288-93. 2005
    ..Appreciation of this species or weight dependence should guide researchers in selecting animal species and designing optimal experiments in the application of allometric scaling...
  97. ncbi Long-term clearance kinetics of inhaled ultrafine insoluble iridium particles from the rat lung, including transient translocation into secondary organs
    M Semmler
    GSF National Research Center, Institute for Inhalation Biology, Neuherberg Munich, Germany
    Inhal Toxicol 16:453-9. 2004
    ..1983) and Bailey et al. (1985)...
  98. ncbi Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance
    Dermot F McGinnity
    Department of Physical and Metabolic Science, AstraZeneca R and D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK
    Drug Metab Dispos 32:1247-53. 2004
    ....
  99. ncbi Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide
    Marion de Jong
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    J Nucl Med 46:1696-700. 2005
    ..111)In-Diethylenetriaminepentaacetic acid (DTPA)]octreotide was used as a practical model of peptide...
  100. ncbi Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution
    Hamidreza Montazeri Aliabadi
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada T6G 2N8
    Biomaterials 26:7251-9. 2005
    ..Our results show that PEO-b-PCL micelles can effectively solubilize CsA, at the same time confining CsA to the blood circulation and restricting its access to tissues such as kidney, perhaps limiting the onset of toxicity...
  101. pmc A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
    Kaci L Osenga
    The University of Wisconsin Madison, Madison, Wisconsin, USA
    Clin Cancer Res 12:1750-9. 2006
    ..Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory neuroblastoma and other GD2-positive solid tumors...

Research Grants68

  1. Insulin Clearance: Candidate and Positional Genetic Determinants
    MARK GOODARZI; Fiscal Year: 2012
    ..and AMPD2) and the AMP-activated protein kinase (AMPK) 12 subunit are associated with variation in the metabolic clearance rate of insulin (MCRI)...
  2. Genetic &Epidemiologic Predictors of Glucose Homeostasis Measures in Hispanics
    Richard M Watanabe; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Insulin sensitivity, metabolic clearance rate of insulin (MCRI), and insulin secretion are traits that all have a significant impact on the risk of type 2 diabetes (T2DM)...
  3. PINEAL FUNCTION IN CHILDHOOD AND ADOLESCENCE
    Anita Cavallo; Fiscal Year: 1990
    ..circadian and seasonal variations, cycles of light/dark and sleep/wake activity, body size, metabolic clearance rate) may account for many of the discrepancies in published data...
  4. MECHANISMS GOVERNING INITIATION OF OVULATION
    Douglas Foster; Fiscal Year: 1980
    ..Changes in metabolic clearance rate and binding proteins for estradiol will be examined...
  5. REFLEX CONTROL OF COMPENSATORY RENAL GROWTH & FUNCTION
    Michael Humphreys; Fiscal Year: 1992
    ..and relating this to simultaneous plasma and pituitary contents of gamma-MSH; (5) determining the metabolic clearance rate of gamma-MSH, before and after acute unilateral nephrectomy...
  6. Development of Superagonist Analogs of Recombinant Human TSH for Imaging and Ther
    Bruce Weintraub; Fiscal Year: 2009
    ..accurately and identically to rigorous HPLC methods which will then be used to determine the IV metabolic clearance rate and the IP, SC and IM phamacokinetics in rodents...
  7. Polycystic Ovary Syndrome: Role of Insulin Resistance
    JOHN NESTLER; Fiscal Year: 2009
    ..3) if acutely increasing circulating insulin in non obese women with PCOS increases uCIDCI and/or the metabolic clearance rate of DCI...
  8. THYROID GLAND PHYSIOLOGY IN HEALTH AND DISEASE
    INDER CHOPRA; Fiscal Year: 1990
    ..We shall develop methods to study serum and urinary concentration, metabolic clearance rate (MCR) and production rate of thyronine (TO), the ultimate product of thyroid hormone metabolism...
  9. MECHANISM(S) OF ACTH ACTION ON TESTOSTERONE DYNAMICS
    Richard Andersen; Fiscal Year: 1980
    ..a direct one at the testicular level or an adrenal mediated one; 2) determine the effect of ACTH on the metabolic clearance rate (MCR) of T...
  10. HAART Regimens in Substance Abusers
    David Greenblatt; Fiscal Year: 2003
    ....
  11. Metabolic Consequences of HAART: CYP3A and P-gp
    David Greenblatt; Fiscal Year: 2003
    ..This multidisciplinary proposal provides a clinical and scientific basis to assess the effects of currently available as well as experimental HAART medications on human CYP3A and P-gp. ..
  12. RADIOTRACER R & D IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2004
    ....
  13. GARLIC PREPARATIONS AND ANTIRETROVIRAL DRUGS
    David Greenblatt; Fiscal Year: 2004
    ..The work will provide immediately applicable clinical data on garlic interactions with antiretrovirals, as well as mechanistic data identifying the interaction process and its predictability from in vitro models. ..
  14. MDR1 and Related Proteins during HIV PI Exposure
    David Greenblatt; Fiscal Year: 2005
    ..The findings will be of importance in understanding lipid disorders related to PIs as well as the kinetics of drugs used to treat HIV and related disorders. ..
  15. CHRONIC BENZODIAZEPINES: BEHAVIOR AND NEUROCHEMISTRY
    David Greenblatt; Fiscal Year: 2005
    ....
  16. Safety of Nicotine Reduction Strategy
    Neal Benowitz; Fiscal Year: 2009
    ..The proposed research is needed to guide governmental regulators as to how best to regulate nicotine in cigarettes and is an essential first step in examining the feasibility of a national regulation program. ..
  17. Addiction and the Brain: Are We Hard Wired to Abuse Drugs
    Joanna Fowler; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  18. RADIOTRACER R & D IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2002
    ....
  19. ANTIRETROVIRAL THERAPIES AND SUBSTANCE ABUSE
    David Greenblatt; Fiscal Year: 2002
    ..The in vitro model, if validated, has the potential to provide clinically important information on interactions involving HIV treatments and abusable drugs, at relatively low cost and with no human drug exposure. ..
  20. CYP3A Function in Aging AfricanAmericans
    David Greenblatt; Fiscal Year: 2006
    ..This study should provide important mechanistic information on the role of age, gender, and ethnicity as sources of variability in CYP3A-mediated drug metabolism and response. ..
  21. Imaging of Serotonin Transporters in Depression
    RAMIN PARSEY; Fiscal Year: 2005
    ..These goals will be met by a combination of didactic I course work and supervision. ..
  22. Biological Predictors of Response to Antidepressants
    Ramin V Parsey; Fiscal Year: 2010
    ..Our overall goal is to reduce the trial and error associated with finding an effective antidepressant by using data from pre-treatment quantification of 5-HT1A receptors and 5-HTT to guide antidepressant treatment selection. ..
  23. HEART IMAGING AGENTS--STRUCTURAL MECHANISTICS STUDY
    David Raffel; Fiscal Year: 2004
    ..Finally, [11C]- and [18F]-labeled polar derivatives of the psychostimulant methcathinone will be synthesized as potential NET markers and their in vitro NET affinities determined as the cloned human NET transporter. ..
  24. Transporter-Enzyme Interplay Evaluation via Microfluidiic HTS Cell Culture Device
    Leslie Benet; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  25. Mitochondria And Metabolic Complications Of HIV
    Pablo Tebas; Fiscal Year: 2006
    ..In order to do this we will use a NASBA based assay to measure the mitochondrial DNA and RNA content in PBMCs, and use 2000 specimens collected longitudinally in 3 large ACTG studies. ..
  26. AIDS CLINICAL TRIALS UNIT
    Pablo Tebas; Fiscal Year: 2007
    ..The investigators have credentials in basic and patient-oriented clinical research. ..
  27. Pretargeting mouse tumor with anti-PSMA antibody-MORF
    Guozheng Liu; Fiscal Year: 2005
    ..Based on our experiences in this pretargeting strategy, we are confident that these investigations on the pretargeting imaging of prostate cancer models with MORFs will be successful. ..
  28. HEART IMAGING AGENTS--STRUCTURAL MECHANISTICS STUDY
    David Raffel; Fiscal Year: 2001
    ..Finally, [11C]- and [18F]-labeled polar derivatives of the psychostimulant methcathinone will be synthesized as potential NET markers and their in vitro NET affinities determined as the cloned human NET transporter. ..
  29. Ontogeny of Drug Bioactivation and Idiosyncratic ADRs
    JAMES LEEDER; Fiscal Year: 2007
    ..abstract_text> ..
  30. PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME
    JAMES LEEDER; Fiscal Year: 2003
    ..It is anticipated that the basic experimental paradigm employed for these studies can also be applied to other idiosyncratic toxicities with suspected drug bioactivation and immune etiologies. ..
  31. New PET Radiotracers-Monoamine Transporters
    Michael Kilbourn; Fiscal Year: 2003
    ....
  32. ACYLCOA FORMATION--COVALENT BINDING, PHARMACOKINETICS
    Leslie Benet; Fiscal Year: 2002
    ....
  33. ANESTHETIC RENAL METABOLISM--MECHANISMS AND CONSEQUENCES
    Evan Kharasch; Fiscal Year: 2002
    ..More broadly, resulting biochemical and clinical insights will be applicable to the numerous other nephrotoxic haloalkenes that are ubiquitous environmental contaminants. ..
  34. Novel noninvasive assessment of cytochrome P450 activity
    Evan Kharasch; Fiscal Year: 2009
    ..This approach may identify inter-individual variability in drug disposition and response;permit more individualized dosing, and reduces the cost of drug interaction studies. ..
  35. Biomaterials as Decorporation Agents for Radionuclides
    TATIANA LEVITSKAIA; Fiscal Year: 2008
    ..abstract_text> ..
  36. Photothermal Imaging of Live Cells
    Vladimir Zharov; Fiscal Year: 2008
    ..The technical realization of PTI is relatively simple, requiring the combination of conventional optical phase-contrast microscopy and the already routinely used nanosecond laser. ..
  37. Mechanisms of Atypical Drug Kinetics and Interactions
    TIMOTHY TRACY; Fiscal Year: 2008
    ..From these data, computer models will be developed to predict the occurrence of atypical kinetics and potential drug interactions to assist in the drug development process. ..
  38. Dietary Isothiocyanates in Cancer Prevention: Effects of Estrogen Metabolism
    Marilyn Morris; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  39. Optimizing the Use of Morphine in Preterm Infants
    John van den Anker; Fiscal Year: 2009
    ..To develop a population PK/PD model of morphine dosing based on gestational age, postnatal age, glomerular filtration rate, and genetic variability in the UGT2B7, mu-opioid receptor and COMT genes. ..
  40. OTK18 Regulation in HIV-1 associated dementia
    Tsuneya Ikezu; Fiscal Year: 2009
    ..abstract_text> ..
  41. Bone-Sparing by Ca Salts With & Without Extra Phosphorus
    Robert Heaney; Fiscal Year: 2008
    ..1 Description, ..
  42. scVEGF Targeted Radiotherapy of Mammary and Colonic Cancer
    FRANCIS GERARD BLANKENBERG; Fiscal Year: 2010
    ..Successful completion of our proposal will give the needed preclinical data for pursuing scVEGF targeted radiotherapy in other models and ultimately clinical applications. ..
  43. Alcohol: Direct and Indirect Effects in Drug Metabolism
    THOMAS BADGER; Fiscal Year: 2008
    ..abstract_text> ..
  44. Mixture Modeling: Pesticide Drug Interactions
    Charles Timchalk; Fiscal Year: 2009
    ..It is fully anticipated that this approach will facilitate the understanding of a variety of complex chemical interactions as it relates to the occupational health implications of working with insecticides. ..
  45. Clinical Trials Methods Workshop - Europe
    Daniel Von Hoff; Fiscal Year: 2008
    ..And, finally, a proven evaluation system is in place to demonstrate that the Workshop will meet its objectives. ..
  46. Physician Training Program in Neonatal Biology
    John Widness; Fiscal Year: 2007
    ..With NIH support beyond that which the investigators currently enjoy, the investigators will be able to significantly enhance the research training experiences they offer their postdoctoral physician trainees in neonatal medicine. ..
  47. Urinary Podocyte Excretion Using FACS Methodology
    Kevin Lemley; Fiscal Year: 2003
    ..e. is podocyturia an earlier biomarker of incipient nephropathy? and 2) do the responses of albuminuria and podocyturia to treatment with angiotensin-converting enzyme inhibitors differ? ..
  48. CORTISOL, CENTRAL OBESITY, AND INSULIN RESISTANCE
    Jonathan Purnell; Fiscal Year: 2003
    ....
  49. FUNGAL PROTEIN/GLYCOPROTEIN EXPRESSION IN TINEA CAPITIS
    Susan Abdel Rahman; Fiscal Year: 2003
    ..abstract_text> ..
  50. PILOT TRIAL IN YOUNG PATIENTS WITH IGA NEPHROPATHY
    Ronald Hogg; Fiscal Year: 2002
    ..From these pilot data, we will determine if a full- scale clinical trial is justified and feasible. if this is the case, a competitive renewal application will be submitted to the NIH. ..
  51. PHARMACOKINETICS OF NICOTINE IN TWINS
    Gary Swan; Fiscal Year: 2002
    ..Ultimately, this knowledge may lead to more informed and more finely targeted treatment of individuals who are either susceptible to nicotine addiction or are already addicted to this substance. ..
  52. BLOOD POOL CONTRAST AGENTS FOR CT AND MRI
    David Vera; Fiscal Year: 2002
    ..Additionally, this structure will serve as a neural carrier of for future class of nonparticulate receptor-binding CT and MR contrast media. ..
  53. PROSPECTIVE STUDY OF TARDIVE DYSKINESIA DEVELOPMENT
    John Kane; Fiscal Year: 2001
    ..This strategy will provide a rapid and cost-effective answer to a critical question. ..
  54. NOVEL A RING AND E RING MODIFIED CAMPTOTHECIN ANALOGS
    Daniel Von Hoff; Fiscal Year: 2001
    ..abstract_text> ..
  55. NOVEL THERAPIES FOR ACETAMINOPHEN TOXICITY
    Laura James; Fiscal Year: 2004
    ..abstract_text> ..
  56. Novel therapeutics for chronic pain
    Paul Wood; Fiscal Year: 2005
    ....
  57. Size-Dependent Uptake of Tc(I)-Labeled RGD Analogs
    David Vera; Fiscal Year: 2005
    ..In that case, a tissue that does not contain the target receptor is used as a reference whereas in this study, the dextran control without the RGD peptide will serve as the reference. ..
  58. VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
    David Haas; Fiscal Year: 2006
    ..The proposed ACTU will not only enroll patients into ACTG clinical trials, but will provide the ACTG the ability to address important questions concerning AIDS treatment and pathogenesis. ..
  59. Characterizing Tissue Development Under Biaxial Loading
    Alvin Yeh; Fiscal Year: 2006
    ..This novel experimental platform will form the basis for novel and innovative studies in mechanobiology. ..
  60. Integrated optical imaging rat of mesentery
    Vladimir Zharov; Fiscal Year: 2004
    ..The technical realization of this new imaging system is relatively simple, combining transmission microscopy and laser technique already routinely in use. ..
  61. Cardiac Function and Cardiac iron (T2*) in Thalassemia
    John Wood; Fiscal Year: 2007
    ..These studies will provide the necessary groundwork for longitudinal studies of cardiac iron load on cardiac performance in thalassemia patients. ..
  62. Classes and Stages of Adolescent Alcohol Involvement
    John Donovan; Fiscal Year: 2009
    ..Establishing the stages of adolescent alcohol involvement and the risk factors for transitions among these stages should facilitate the design of more effective prevention and intervention efforts in this population. ..
  63. Localized modulation of RPE P-gp/MRP activity for back-of-the-eye drug delivery
    Soumyajit Majumdar; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  64. Evaluation of a Biomarker for Acetaminophen Toxicity
    Laura James; Fiscal Year: 2005
    ..The data generated from this study will lead to enhanced recognition of APAP hepatotoxicity, thus allowing for better identification of "at risk" populations and the creation of prevention strategies. ..
  65. Novel Cationic 99mTc Complexes for Heart Imaging
    Shuang Liu; Fiscal Year: 2006
    ..Successful development of new 99mTc perfusion imaging agents will have a profound impact on diagnostic evaluation, risk stratification, and therapeutic decision-making in patients with CAD. ..
  66. CNS Viral Dynamics and Cellular Immunity During AIDS
    David Haas; Fiscal Year: 2009
    ..Characterizing these relationships will expand our knowledge regarding key events that lead to AIDS dementia, and may suggest novel approaches to other immunologic or viral-mediated diseases that affect the brain. ..
  67. CVD RISK FACTORS AND BRAIN MORPHOLOGY IN NHLBI TWINS
    Gary Swan; Fiscal Year: 2001
    ....